Enanta Pharmaceuticals (ENTA) PT Raised to $36 at Baird; Remains Sidelined

August 8, 2017 7:19 AM

Baird raised its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $36.00 (from $27.00) while maintaining a Neutral rating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found